SCHEMBL1746647

SCHEMBL1746647

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)C(O)C2O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)O)C(O)C1O

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 7/20 0.84
P2RY2 P41231 4/20 0.84
P2RX1 P51575 4/20 0.84
P2RX3 P56373 4/20 0.84
SRC P12931 2/20 0.84
SMN1; SMN2 Q16637 2/20 0.84
P2RX2 Q9UBL9 2/20 0.84
ALDH1A1 P00352 2/20 0.84
P2RX4 Q99571 1/20 0.84
TRPM2 O94759 2/20 0.80
TAS1R3 Q7RTX0 2/20 0.80
TAS1R1 Q7RTX1 2/20 0.80
DNPH1 O43598 1/20 0.80
PRKAB2 O43741 1/20 0.80
LDHA P00338 1/20 0.80
ADRB2 P07550 1/20 0.80
FBP1 P09467 1/20 0.80
ADORA1 P30542 1/20 0.80
PRKAG1 P54619 1/20 0.80
PRKAA2 P54646 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL459997 1.00 P2RY1 (0.84) P2RY1P2RY2P2RX1P2RX3SRC
SCHEMBL459771 1.00 P2RY1 (0.84) P2RY1P2RY2P2RX1P2RX3SRC
SCHEMBL10396861 0.99 P2RY1 (0.86) P2RY1P2RY2P2RX1P2RX3SRC
Water SCHEMBL9225179 0.99 P2RY1 (0.82) P2RY1P2RY2P2RX1P2RX3SRC
SCHEMBL3792441 0.99 P2RY1 (0.82) P2RY1P2RY2P2RX1P2RX3SRC
SCHEMBL5838786 0.99 P2RY1 (0.82) P2RY1P2RY2P2RX1P2RX3SRC
SCHEMBL28646263 0.98 P2RY1 (0.84) P2RY1P2RY2P2RX1P2RX3SRC
SCHEMBL28367704 0.98 P2RY1 (0.84) P2RY1P2RY2P2RX1P2RX3SRC
SCHEMBL6242721 0.98 P2RY1 (0.84) P2RY1P2RY2P2RX1P2RX3SRC
SCHEMBL27962220 0.97 P2RY1 (0.80) P2RY1P2RY2P2RX1P2RX3SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8608922-B2 Biosensor for continuous monitoring of metabolites and proteins and methods of manufacture thereof THE UNIVERSITY OF CONNECTICUT (US) 2013-12-17 US claimed
US-20100116691-A1 BIOSENSOR FOR CONTINUOUS MONITORING OF METABOLITES AND PROTEINS AND METHODS OF MANUFACTURE THEREOF UNIVERSITY OF CONNECTICUT (US) 2010-05-13 US claimed
EP-0969848-A1 USE OF DIADENOSINE POLYPHOSPHATES FOR REDUCING BLOOD PRESSURE Clemson University (US) 2000-01-12 EP claimed
WO-1998030222-A1 USE OF DIADENOSINE POLYPHOSPHATES FOR REDUCING BLOOD PRESSURE CLEMSON UNIVERSITY (US) 1998-07-16 WO claimed
US-12181435-B2 Methionine concentration measurement method KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2024-12-31 US disclosed
US-20230016698-A1 METHOD FOR DETERMINING GLUCOSE CONCENTRATION IN A SERUM SAMPLE KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2023-01-19 US disclosed
US-20230003682-A1 METHIONINE CONCENTRATION MEASUREMENT METHOD KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2023-01-05 US disclosed
US-11474067-B2 Detection of serum methionine and glucose by graphite pencil electrode KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2022-10-18 US disclosed
US-11192915-B2 Synthesis of polyphosphorylated molecules from polyphosphates MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-12-07 US disclosed
US-20200141891-A1 DETECTION OF SERUM METHIONINE AND GLUCOSE BY GRAPHITE PENCIL ELECTRODE KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2020-05-07 US disclosed
US-20190137433-A1 METHOD FOR DETECTING URIC ACID KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2019-05-09 US disclosed
US-20190137432-A1 REDUCED GRAPHENE OXIDE-BASED GRAPHITE ELECTRODE KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2019-05-09 US disclosed
US-20100116691-A1 BIOSENSOR FOR CONTINUOUS MONITORING OF METABOLITES AND PROTEINS AND METHODS OF MANUFACTURE THEREOF UNIVERSITY OF CONNECTICUT (US) 2010-05-13 US disclosed
WO-2009020860-A1 METHOD FOR DIAGNOSING ACUTE CARDIAC ISCHEMIA VIRGINIA COMMONWEALTH UNIVERSITY (US) 2009-02-12 WO disclosed
EP-0969848-A1 USE OF DIADENOSINE POLYPHOSPHATES FOR REDUCING BLOOD PRESSURE Clemson University (US) 2000-01-12 EP disclosed
EP-0969848-A1 USE OF DIADENOSINE POLYPHOSPHATES FOR REDUCING BLOOD PRESSURE Clemson University (US) 2000-01-12 EP disclosed
WO-1998030222-A1 USE OF DIADENOSINE POLYPHOSPHATES FOR REDUCING BLOOD PRESSURE CLEMSON UNIVERSITY (US) 1998-07-16 WO disclosed
WO-1998030222-A1 USE OF DIADENOSINE POLYPHOSPHATES FOR REDUCING BLOOD PRESSURE CLEMSON UNIVERSITY (US) 1998-07-16 WO disclosed
US-5716797-A CONTAINING THIOGLYCEROL, 2-MERCAPTOETHANOL AND/OR 2-MERCAPTOETHANESULFONIC ACID OR ITS SALT AS CREATINE KINASE REACTIVATOR WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 1998-02-10 US disclosed
EP-0721986-A2 Creatine kinase reagent WAKO PURE CHEMICAL INDUSTRIES LTD (JP) 1996-07-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192915-B2 Synthesis of polyphosphorylated molecules from polyphosphates PNKP, PPA1, PPIP5K2 P2RY1 553/4885P2RY2 650/4885P2RX1 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.